SKYE News

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc.(SKYE) of a Class Action Lawsuit and an Upcoming Deadline

Skye Bioscience, Inc. (SKYE) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of January 16, 2026 Deadline

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity USA - English APAC - English APAC - Traditional Chinese

SKYE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Class Action Filing Initiated by Pomerantz LLP Against Skye Bioscience, Inc. – SKYE

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE ALERT: Securities Fraud Class Action Launched Against Skye Bioscience, Inc. - January 16, 2026 Deadline

Class Action Filing Announced by Pomerantz LLP Concerning Skye Bioscience, Inc. – SKYE

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Skye Bioscience, Inc. (SKYE) Investors of January 16, 2026 Deadline